Originally published In Press as doi:10.1074/jbc.M001562200 on September 15, 2000
J. Biol. Chem., Vol. 275, Issue 51, 39954-39963, December 22, 2000
Ca2+-activated K+ Channels in Human
Leukemic Jurkat T Cells
MOLECULAR CLONING, BIOCHEMICAL AND FUNCTIONAL
CHARACTERIZATION*
Rooma
Desai
,
Asher
Peretz
,
Hirsh
Idelson§,
Philip
Lazarovici¶, and
Bernard
Attali
From the
Department of Neurobiology, The Weizmann
Institute of Science, 76100 Rehovot, Israel, § Alomone Labs,
Jerusalem, 91042, Israel, and the ¶ Department of Pharmacology and
Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The
Hebrew University of Jerusalem, Jerusalem 91120, Israel
Received for publication, February 24, 2000, and in revised form, September 15, 2000
 |
ABSTRACT |
Previous studies have demonstrated the presence
of apamin-sensitive, small-conductance Ca2+-activated
K+ currents in human leukemic Jurkat T cells. Using a
combined cDNA and reverse transcriptase-polymerase chain
reaction cloning strategy, we have isolated from Jurkat T cells
a 2.5-kilobase cDNA, hSK2, encoding the human
isoform of SK2 channels. Northern blot analysis reveals the presence of
a 2.5-kilobase hSK2 transcript in Jurkat T cells. While
present in various human tissues, including brain, heart, skeletal
muscle, kidney, and liver, no hSK2 mRNA could be
detected in resting and activated normal human T cells. The hSK2 gene is encoded by 8 exons and could be assigned to
chromosome 5 (q21.2-q22.1). The protein encoded by hSK2 is
579 amino acids long and exhibits 97% identity with its rat
counterpart rSK2. When expressed in Chinese hamster ovary cells,
hSK2 produces Ca2+-activated K+
currents with a unitary conductance of 9.5 pS and a
K0.5 for calcium of 0.7 µM; hSK2
currents are inhibited by apamin, scyllatoxin, and
d-tubocurarine. Overexpression of the Src family tyrosine kinase p56lck in Jurkat cells, up-regulates SK2 currents by
3-fold. While IKCa channels are transcriptionally induced upon
activation of normal human T cells, our results show that in Jurkat
cells SK2 channels are constitutively expressed and down-regulated
following mitogenic stimulation.
 |
INTRODUCTION |
Ca2+-activated K+ channels (KCa) represent
a class of potassium channels that respond to changes in intracelluar
Ca2+ concentration, and couple Ca2+ metabolism
to K+ flux and membrane excitability. Based on their
electrophysiological properties, three main classes of KCa channels
have been characterized (for review, see Refs. 1-3): the large
conductance, Ca2+- and voltage-gated channels (BK), the
intermediate conductance, voltage-independent channels (IK), and the
small conductance, voltage-independent channels (SK) (1-3). SK
channels have unitary conductance of 4-14 pS, are voltage-independent
and are activated in the range of 200-500 nM
[Ca2+]i.1
Some SK currents are blocked by apamin, an 18-mer peptide toxin from
bee venom and by scyllatoxin, a 31-mer polypeptide scorpion toxin
(4-7). In the brain, they are responsible for the slow after
hyperpolarizing phase of action potentials which modulates the firing
pattern of neurons (1-3). SK channels are also expressed in a wide
variety of peripheral tissues including adrenal cortex, liver,
skeletal, and smooth muscles as well as leukemic Jurkat T cells
(8-19).
Human T lymphocytes are endowed with at least two different types of
K+ channels, voltage-gated K+ channels (Kv) and
KCa channels (for review, see Ref. 20). The Kv channel in human T cells
has been characterized extensively at the physiological and molecular
levels (20). It is encoded by hKv1.3, a
Shaker-related Kv channel gene (21, 22). Two KCa channel
subtypes have been characterized in lymphocytes and lymphocytic cell
lines. The predominant KCa channel found in normal human peripheral T
cells has a 15-40 pS unitary conductance, is a charybdotoxin
(CTX)-sensitive and apamin-insensitive inwardly-rectifying channel that
is also known as intermediate conductance (IK) (23, 24). A gene
encoding IK, called hSK4 (or hIK1, hIKCa1, and
hKCa4) has been recently cloned from various human tissues
(25-28). The prominent KCa channel expressed in the human leukemic
Jurkat T cell line corresponds to an apamin-sensitive,
small-conductance channel (4-7 pS) (16, 17). Recent work (29) showed
that SK2 encodes this KCa current based on the PCR
amplification of a partial Jurkat SK2 cDNA fragment.
Three genes encoding SK channel family members have been cloned from
human (hSK1) and rat brains (rSK2 and
rSK3) (30). These different isoforms encode the pore-forming
subunit of SK channels and exhibit a high degree of sequence
identity with 70-80% amino acid sequence identity. Hydrophobicity
analysis predicts a Shaker-like structure (30). Recent
studies revealed that Ca2+ gating involves the constitutive
association of calmodulin with a C-terminal domain of SK channel
subunits (31-34). Some cloned isoforms of SK channels are blocked by
apamin and by d-tubocurarine (dTC), a plant alkaloid (29,
35-37). The residues Asp341 and Asn368 on
either side of the deep pore of the
subunit were shown to be the
primary determinants of apamin and dTC sensitivity (35).
In this study, we cloned from human Jurkat T cells a 2.5-kb full-length
cDNA, hSK2, encoding the human isoform of SK2 channels. While hSK2 transcripts are found in various human tissues,
including brain, heart, skeletal muscle, kidney, and liver, no
hSK2 mRNA could be detected in normal human T cells.
Based on high-throughput genome sequence analysis (HTGS), we show that
the hSK2 gene is encoded by 8 exons and could be assigned to
human chromosome 5 (q21.2-q22.1). Similar to native Jurkat KCa
currents, hSK2 produces in transfected mammalian cells a
time- and voltage-independent Ca2+-activated K+
current which is inhibited by apamin, scyllatoxin, and dTC. In Jurkat
cells overexpressing the Src family tyrosine kinase p56lck
(LCK+), the SK2 channel activity increases by more than
3-fold. In contrast to IKCa channels which are transcriptionally
induced upon activation of normal human T cells, our data show that in Jurkat cells, SK2 channels are constitutively expressed and are down-regulated following mitogenic stimulation.
 |
EXPERIMENTAL PROCEDURES |
Cells--
Human leukemic Jurkat T cells and the
p56lck-deficient Jurkat cells (LCK
) were
maintained in RPMI culture medium supplemented with 2 mM glutamine, antibiotics, and 10% fetal calf serum in a
humidified, 5% CO2 incubator at 37 °C. The
p56lck-overexpressing Jurkat cells (LCK+)
were generated from LCK
cells which were re-transfected
with p56lck tyrosine kinase and were maintained in the above
medium supplemented with hygromycin B (Roche Molecular Biochemicals,
100 µg/ml). Rat pheochromocytoma PC12 cells were maintained in
Dulbecco's modified Eagle's medium supplemented with 2 mM
glutamine, 8% horse serum, 10% fetal calf serum and antibiotics. HEK
293 and CHO cells were maintained in Dulbecco's modified
Eagle's medium supplemented with 2 mM glutamine,
10% fetal calf serum and antibiotics in a humidified, 5%
CO2 incubator at 37 °C.
Electrophysiology--
Human leukemic T cell line Jurkat,
LCK
, LCK+, hSK2-transfected CHO and HEK 293 cells were plated on poly-L-lysine-coated coverslips settled on a 1.5-ml chamber, mounted on the stage of an Axiovert 35 inverted microscope (Carl Zeiss). Recordings were made at 22 ± 1 °C, using patch pipettes pulled from borosilicate glass
capillaries (fiber filled) with resistance of 4-8 M
.
Patch clamp recordings were performed using standard techniques (38).
For whole cell patch clamp recordings, two different solutions were
used, external high [K+] and physiological solutions. In
the external high K+ solutions, the patch pipette contained
(in mM): 135 K aspartate, 40 KOH, 2 MgCl2, 10 HEPES, 10 EGTA, and 8.7 CaCl2 (1 µM free
Ca2+) adjusted to pH 7.2 with KOH, while the bath solution
contained (in mM): 165 KCl, 2 CaCl2, 2 MgCl2, and 10 HEPES, adjusted to pH 7.2 with KOH. For the
physiological solutions, the patch pipette contained (in
mM): 110 K gluconate, 20 KCl, 1 MgCl2, 5 KATP,
10 HEPES, 5 EGTA, and 4.7 CaCl2 (1 µM free
Ca2+) adjusted to pH 7.4 with KOH, while the bath solution
contained (in mM): 140 NaCl, 5 KCl, 1.8 CaCl2,
1.2 MgCl2, 11 glucose, and 5.5 HEPES, adjusted to pH 7.4 with NaOH. For inside-out patch clamp recording, the pipette solution
(out) contained (in mM): 144 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, adjusted to pH 7.2 with KOH and 2 mM sucrose; the bath solution (in) contained (in
mM): 150 KCl, 40 KOH, 1 MgCl2, 8.2 CaCl2 (0.77 µM free Ca2+), 10 EGTA, and 10 HEPES, adjusted to pH 7.2 with KOH. Solutions were
adjusted with sucrose at ~300-315 mosmol liter
. Series
resistance were compensated by 85-95%. Signals were amplified using
an Axopatch 200B patch clamp amplifier (Axon Instruments) and filtered
at 1-2 KHz, via a 4-pole Bessel filter. Data were sampled at 2.5-10
KHz and analyzed using pClamp 6.0.2 software (Axon Instruments) on an
IBM-compatible 486 computer interfaced with DigiData 1200 (Axon
Instruments). Further data analysis was done using Axograph 3.0 software (Axon Instruments) and Excel 5.0 (MicroSoft) on an Apple
MacIntosh computer.
Membrane Preparation and Western Blotting--
Cells were
harvested and washed twice in cold phosphate-buffered saline and were
then resuspended (1.5 × 107 cells/ml) in cold
homogeneization buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, and 1 mM phenylmethylsulfonyl
fluoride, 10 µg/ml leupeptin, and 10 µg/ml aprotinin). Cells were
homogenized with a Teflon glass homogenizer and the homogenate was
centrifuged at 1,000 × g for 5 min (at 4 °C) to
remove large cell debris. The supernatant was centrifuged at
21,000 × g for 30 min (at 4 °C) and the membrane
pellet (crude membrane fraction) was resuspended in cold
homogeneization buffer and sonicated for 30 s. The membrane homogenates were then aliquoted, quickly frozen in liquid nitrogen and
stored at
70 °C until use. Western blots were performed as described (39). Polyclonal anti-rat SK2 antibodies and anti-human Kv1.3
antibodies (Alomone labs) were used at 1.5 µg/ml.
Transfections--
For electrophysiological recording, CHO and
HEK 293 cells were transfected with hSK2 subcloned into the
pCDNA3 vector (Invitrogen). Cells were seeded (5.104
cells/well) on poly-L-lysine-coated glass coverslips in
24-multiwell plates. Transfection was performed according to the
manufacturer's protocol (Life Technologies, Inc.) using 1.5 µl of
LipofectAMINE and 0.25 µg of hSK2-pCDNA3 together with 0.5 µg
of pIRES-CD8 (kindly provided by Drs. J. Barhanin and A. Patel, CNRS,
Sophia Antipolis, France), as a marker for transfection. Transfected
cells were visualized 48 h following transfection, using the
anti-CD8 (Dynal) antibody-coated beads method (40).
Molecular Cloning of hSK2--
Total RNA from Jurkat T cells was
isolated as described (41) and poly(A+) RNA was isolated
using oligo(dT)-Sepharose (Collaborative Research). Single-stranded
cDNA was synthesized from 5 µg of total RNA or 250 ng of
poly(A+) RNA using 200 units of Superscript
IITM RNase H
reverse transcriptase (Life
Technologies, Inc.). The cDNA was primed either with the
tagged oligo(dT) primer
5'-CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTT-3' or with
random primers. The single-stranded cDNA was used as a template for
PCR. Degenerate primers were designed on the basis of the homology
between the different SK channel isoforms: rSK1, rSK2, rSK3,
and hSK1. The primers 5'-ATHTTYGGNATGTTYGGNA-3' (primer A)
and 5'-CCACATNGCNCCNARRAARTT-3' (primer B), were used to PCR amplify from Jurkat T cells the initial 633-bp fragment of
hSK2. All PCR reactions were performed using the proof
reading Pfu DNA polymerase (Promega). The sequence was
further extended by a 5' and 3' rapid amplification of cDNA
ends-PCR cloning strategy (42) and a poly(A)-tailed cDNA fragment
of 2166 bp length was obtained. A blastn search of the
GenBankTM data base at the National Center for
Biotechnology Information was performed. Human expressed sequence tags
overlapping the 5' (EST: AI339865 and AI271784) and 3' (EST: AI700829
and AI680869) untranslated regions of our 2166-bp cDNA were found. The EST AI339865 further extended the 5'-UTR sequence by 343 bp. The
whole cDNA sequence of 2509 bp was amplified by RT-PCR from Jurkat
mRNA confirming the co-linearity of the overlapping cDNA fragments.
Northern Blot Analysis--
Human 12-lane multiple tissue and
Human Cancer Cell Line MTNTM blots
(CLONTECH) were used. For Jurkat cells, 5 µg of
mRNA were resolved by electrophoresis on a 1 M
formaldehyde, 1% agarose gel and then blotted overnight onto a
Hybond-N membrane (Amersham) in 20 × SSC (3 M sodium
chloride, 0.3 M sodium citrate, pH 7.0). The Northern blots
were probed with a [32P]dCTP-labeled 660-bp DNA probe
spanning the extreme C-terminal region (including the 3'-UTR) of the
hSK2 cDNA. Another 5' specific hSK2 probe
which consisted in the whole 456-bp 5'-UTR, was used to check the
specificity of the Northern signals. Hybridization was carried out at
68 °C for 1 h using the solutions
(CLONTECH) and according to the manufacturer's
protocol (CLONTECH). Signal was visualized with a
PhosphorImager 445 SI, after 16-23 h exposure.
 |
RESULTS |
Human Leukemic Jurkat T Cells Express Apamin- and dTC-sensitive SK
Currents--
Jurkat T cells are known to express both Kv and SK
currents (16, 17). To identify SK currents, we used the whole cell configuration of the patch clamp technique. SK channels were activated by employing a high capacity Ca2+-buffered pipette solution
at free [Ca2+]i of 1 µM. Currents
were recorded in external high K+ solutions (165 mM K+, see "Experimental Procedures"),
using voltage ramps of 400 ms from
160 to +40 mV, to identify both Kv
and SK currents (Fig. 1, A and
B). Under these experimental conditions, Kv currents activated at potentials positive to
40 mV leading to inward currents below and outward currents above 0 mV. SK currents were clearly identified at potentials below
50 mV, as the SK channel slope conductance increased at negative potentials, while that of Kv is
minimal. Similar Kv and SK current components were previously described
using the same recording solutions (16, 17). Fig. 1D shows
the same SK current recorded, using a different protocol in which cells
were stepped from
120 to
10 mV from a 0-mV holding potential. Note
that at very negative potentials, the SK current is partially
contaminated by the deactivating tail of the Kv1.3 current which does
not totally inactivate at a holding potential of 0 mV. In agreement
with previous work (17), we found that apamin (5 nM) and
dTC (10 µM) inhibit Jurkat SK currents by 70% (Fig. 1,
A-C). In contrast, this current is insensitive to 100 nM CTX and 100 nM DTX (data not shown).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 1.
Pharmacology of SK currents in Jurkat
cells. A and B, ramp currents before and
after 5 nM apamin (A) and 10 µM
dTC (B). From a holding potential of 0 mV, cells were
subjected to a ramp of 400 ms from 160 to +40 mV. The dotted
line represents the zero current level. C, current
amplitude as measured at 140 mV (pA ± S.E.) in cells before
(control, n = 22) and after exposure to apamin (5 nM, n = 13) and dTC (10 µM,
n = 10). Results are statistically significant (*
p < 0.01). D, from a holding potential of 0 mV, cells were stepped for 100 ms from 120 to 10 mV in 10-mV
increments. SK currents were recorded in external high K+
solutions.
|
|
Molecular Cloning of hSK2 in Jurkat T Cells--
To identify
unambiguously the molecular isoform encoding the Jurkat SK channel,
degenerate primers were designed based on the homology existing between
the previously cloned SK channels rSK1, rSK2, rSK3, and
hSK1 (30) and an RT-PCR was performed. The primers spanning
the middle of the S1 segment (primer A) and the N-terminal boundary of
the pore domain (primer B, see Fig. 2 and
"Experimental Procedures") amplified an initial cDNA fragment of 633 bp, which was highly homologous to rSK2. The sequence
was further extended by a 5' and 3' rapid amplification of cDNA
ends-PCR cloning strategy (42) and a poly(A)-tailed cDNA fragment
of 2166 bp length was obtained. A blastn search of the
GenBankTM data base at the National Center for
Biotechnology Information was performed. A human expressed sequence tag
(EST AI339865) overlapping the 5'-untranslated region of our 2166-bp
cDNA was found. This EST further extended the 5'-UTR sequence by
343 bp. The whole cDNA sequence of 2509 bp was amplified by RT-PCR
from Jurkat mRNA and sequenced, confirming the co-linearity of the overlapping cDNA fragments. Thus, the whole cDNA obtained (2509 bp) probably corresponds to the full-length mRNA in Jurkat T cells since in Northern blots, a 2.5-kb transcript was detected (Fig. 3A). Neither SK1 nor SK3 could
be amplified from Jurkat cDNA (Ref. 29, and not shown).

View larger version (137K):
[in this window]
[in a new window]
|
Fig. 2.
Amino acid sequence alignment of hSK2 with
rSK2, aSK2, hSK3, rSK3, hSK1, and
rSK1. Sequences were aligned using ClustalW 1.7 at the BCM search launcher using the default parameters. Gaps are
represented by a dash. The putative transmembrane domains
(S1-S6) and the pore region are boxed. Identical residues
are shaded gray. Positions of the initial degenerate primers
A and B, used for RT-PCR cloning of hSK2 from
Jurkat cell mRNA, are indicated as dashed lines above
the corresponding sequence.
|
|

View larger version (84K):
[in this window]
[in a new window]
|
Fig. 3.
Northern blot analysis of hSK2
transcripts. A, a 5' specific hSK2
probe which consisted in the whole 456-bp 5'-UTR was used for the
Northern blot analysis in different human tissues (left
panel), in Jurkat T cells (middle panel), and different
tumorigenic cell lines (right panel). B, a human
-actin probe was used as a standard positive control to
re-probe the blots after stripping for input mRNA.
|
|
The Jurkat cDNA which we termed hSK2, corresponds to the
human isoform of the rat rSK2 sequence. It comprises an open
reading frame of 1737 bp (nucleotide position 457-2193), a 456-bp
5'-UTR and a 333-bp 3'-UTR ended with a polyadenylation signal and a poly(A+) tail. The putative initiation codon has a Kozak
consensus sequence GCCATGA (43), although we did not detect
an in-frame stop codon upstream the initiator ATG (nucleotide position
457). The protein encoded by hSK2 is 579 amino acids long
and exhibits 97% identity with its rat protein counterpart
rSK2 (Fig. 2). Except for the N terminus which exhibits
minor differences between hSK2 and rSK2 (amino
acids 51-54 and 99-102), the protein sequences are virtually identical for both species (Fig. 2). The predicted hSK2 protein contains several consensus cAMP-dependent protein kinase,
casein kinase II and protein kinase C phosphorylation sites at the N and C termini. Like rSK2, hSK2 does not possess
N-glycosylation sites at predicted extracellular locations.
Tissue Distribution, Phylogenetic Tree, and Chromosomal
Localization--
Northern blot analysis performed in various human
tissues reveals a major 2.5-kb hSK2 transcript in Jurkat T
cells, liver, kidney, and brain with the strongest signals in liver and
brain (Fig. 3A). Higher molecular weight transcripts (4.4 kb) were found in heart and skeletal muscle, while a lower mRNA
species (1.3 kb) was also observed in brain and liver (Fig.
3A). The 4.4-kb transcript may represent a cross-reactive
mRNA species from the SK channel family although a 5' specific
hSK2 probe which consisted in the whole 456-bp 5'-UTR, was
used to check the specificity of the Northern signals (Fig.
3A). No detectable transcripts were observed in small
intestine, placenta, lung, thymus, spleen, and normal peripheral T
cells (Fig. 3A and see also, Fig. 7C).
Interestingly, hSK2 is expressed in melanocytes (EST
AA418096) and fetal heart (EST AA418000). Since hSK2 is not
expressed in normal spleen, thymus, and peripheral T cells, we checked
for the presence of hSK2 mRNA in some human tumor cell
lines to test whether the expression of SK2 is a marker of certain
T-cell malignancies. No hSK2 transcript was detected in
promyelocytic leukemia HL-60, HeLa S3, chronic myelogenous leukemia
K-562, lymphoblastic leukemia MOLT-4, Burkitt's lymphoma Raji,
colorectal adenocarcinoma, lung carcinoma A549, and melanoma G-361
cells (Fig. 3A). A recent study showed that these
tumorigenic cell lines express hIKCa1 channel mRNA (44). Thus, the
presence of hSK2 seems to be specific to the leukemic Jurkat
T cells.
The phylogenetic relationships of 23 different SK and IK channel
GenBankTM entries and of hSK2 were examined
(Fig. 4A). The amino acid
sequence alignment of the complete open reading frames of all 23 genes was performed using the software ClustalX. The unrooted phylogenetic tree was constructed by the neighbor-joining method after exclusion of
gaps. The tree file was plotted using the software NJplot. Horizontal
branch lengths are drawn to scale, with the bar indicating 0.05 amino acid substitution per site. The SK and IK channel genes are
divided into two main clusters, one of the SK channel family and the
other of the IK channel family with high bootstrap values Fig.
4A). The SK channel family cluster is further subdivided into two clusters with SK2 and SK3 isoforms in
one cluster and the SK1 isoforms in the other cluster. The
IK family genes are subdivided into two main clusters, with the
murine/rodent and human IK genes falling into two different groups
(Fig. 4A).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 4.
Phylogenetic tree, chromosomal localization,
and genomic organization of the hSK2 gene.
A, the phylogenetic tree of different SK and IK channel
GenBankTM entries and of hSK2 was constructed by
aligning the amino acid sequence of all genes using the software
ClustalX and the neighbor-joining method after exclusion of gaps. The
tree file was plotted using the software NJplot. The scale
bar indicates 0.05 amino acid substitution per site. B,
human chromosomal localization was deduced by retrieving human
chromosome 5 contigs (AC010595, AC021085, and AC025761) from the HTGS.
The contigs AC021085 and AC025761 retrieved through electronic PCR, one
STS, D5S2065 (GenBankTM accession number Z54068). On the cytogenetic
map, the D5S2065 STS is mapped to chromosome 5 between the cytogenetic
markers 5q21.2 and 5q22.1. C, the intron-exon junctions are
shown with the corresponding flanking amino acids and genomic
sequences. The consensus GT (donor)-AG (acceptor) splice sites are
found at each junction. Numbers in parentheses at
the acceptor side refer to amino acid positions and nucleotide
positions in the hSK2 cDNA. D, genomic
organization ascertained by analysis of contigs (AC010595, AC021085,
AC025761, AC021415, and AC009589) from HGTS data base. The
hSK2 mRNA is shown, with 5'- and 3'-UTR as bold
lines. Within the ORF, transmembrane segments are drawn as
gray boxes. Introns are shown as roman numbers.
At each exon-intron junction, the indicated number correspond to the
amino acid position at which the exon is flanked by the intron
boundary.
|
|
Although we did not experimentally examine the human chromosomal
localization of hSK2, a Blastn search at the
GenBankTM via the HTGS identified three matching
human chromosome 5 contigs (AC010595, AC021085, and AC025761),
suggesting that hSK2 maps to human chromosome 5. Furthermore, we performed an electronic PCR scanning the sequence of
these three chromosome 5 contigs in dbSTS data base. The contigs
AC021085 and AC025761 retrieved one STS, D5S2065 (GenBankTM
accession number Z54068). On the Marshfield map, D5S2065 is mapped to
chromosome 5 at position 122.01 (centimorgan). On the WI-YAC and
genethon maps, D5S2065 is assigned to chromosome 5 at positions 389 (ordinal) and 121.70 (centimorgan), respectively. On the cytogenetic
map, the D5S2065 STS is mapped to chromosome 5 between the cytogenetic
markers 5q21.2 and 5q22.1 (Fig. 4B). In the vicinity of this
locus, are found the genes encoding the polysialytransferase,
mannosidase, the fer tyrosine kinase,
Ca2+-calmodulin kinase type IV, and the adenomatous
polyposis coli gene which is responsible for colorectal cancers.
However, in the OMIM map no obvious diseases seem to be linked to the
hSK2/KCNN2 locus.
Exploiting the high-throughput genome sequence data base and performing
a Blast analysis and sequence alignments of the hSK2 cDNA with the chromosome 5 contigs (AC010595, AC021085, AC025761,
AC021415, and AC009589), we could ascertain the genomic organization of
the hSK2/KCNN2 gene (Fig. 4, C and D).
Analysis of these clones shows that hSK2/KCNN2 is encoded by
8 exons, with 4 intron-exon junctions within the core domain and 3 intron-exon boundaries at the C terminus of the hSK2 channel sequence
(Fig. 4, C and D).
Functional Expression of hSK2--
To study the functional
properties of hSK2, we transfected either CHO or HEK 293 cells with an expression vector encoding only the hSK2
coding region. Fig. 5B shows
typical macroscopic current traces obtained from a CHO cell, patched
with 0.96 µM free Ca2+ in the pipette
solution, and 5 mM K+ in the bath medium
(physiological solution). Under these conditions, a time- and
voltage-independent outward K+ current was elicited by
depolarizing test pulses from
120 to +40 mV from a
85 mV holding
potential (Fig. 5B). Similar results were obtained in HEK
293 cells (not shown). In extracellular high K+ solutions
(165 mM K+), voltage ramps evoked quasi-linear
hSK2 currents with weak inward rectification at positive potentials
(Fig. 5C). A similar inward rectification was also observed
for rSK2 expression in HEK 293 cells (37). A few minutes after break-in
to the whole cell configuration, the hSK2 current has the tendency to
run-up over time for more than 2-fold (Fig. 5C). This slow
increase in SK2 current is not caused by an increase in leak
conductance and occurs for time periods which exceed by far that needed
for diffusion of free Ca2+ from the pipette solution to the
cell. This current run-up has been also observed for hSK1 and rSK2
channels expressed in HEK 293 cells (37), however, the mechanism
underlying this phenomenon is presently unclear. In the absence of
Ca2+ in the pipette solution, no SK current could be
produced (Fig. 5F). The reversal potential of the current
shifted by 59 mV per 10-fold change in external K+
concentration, in close agreement with the predicted value of the
Nernst equation for a K+ selective current. The
Erev were +2.2 ± 0.4 mV (n = 5),
35.6 ± 0.3 mV (n = 7) and
86.2 ± 1.0 mV (n = 9) at 155, 40, and 5 mM
[K+]o, respectively. In line with the
pharmacological characteristics of the SK current expressed by Jurkat T
cells (17) and that evoked by expression of the cloned rSK2 channel
(29, 30, 37), hSK2 cDNA expressed a K+
current that was sensitive to block by apamin (5 nM),
scyllatoxin (0.5 nM), and dTC (10 µM) with
78, 54, and 64% of current inhibition, respectively (Fig. 5,
D-F). The hSK2 current was insensitive to block by CTX or
DTX (not shown).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of hSK2 in
transfected CHO cells. A and B, whole cell
currents were recorded in physiological solutions from non-transfected
(A) and hSK2-transfected (B) CHO cells. From a
holding potential of 85 mV, the membrane potential was stepped for
400 ms from 120 to +40 mV in 20 mV increments. C,
representative ramp current recorded from a hSK2-transfected CHO cell
at a holding potential of 0 mV in external high K+
solutions, by a ramp of 340 ms from 130 to +40 mV. To illustrate the
run-up of hSK2 current, consecutive ramps are shown from 3 min up to 15 min following break-in to the whole cell configuration. D
and E, representative ramp currents recorded as in
C before and after application of 0.5 nM
scyllatoxin (D) and 10 µM dTC (E).
F, current-voltage relationships for control untransfected
(solid squares, n = 9), hSK2-transfected
cells with no Ca2+ in the pipette solution (empty
triangles, n = 5), and hSK2-transfected cells with
1 µM free Ca2+ in the pipette solution which
have been treated with 5 nM apamin (open
squares, n = 9) or 10 µM dTC
(open circles, n = 8). The voltage protocol
is as in A and B.
|
|
We determined next, the unitary conductance and the calcium dependence
of the hSK2-induced K+ currents in transfected CHO cells
(Fig. 6). Using inside-out patches, we
found that the single-channel conductance of hSK2 is 9.5 ± 0.7 pS
(n = 5) (Fig. 6, B and C), a
value very close to that obtained previously for recombinant rSK2 (30).
The Ca2+ sensitivity of hSK2 was obtained from inside-out
macropatches and the Hill plot derived K0.5 = 0.70 ± 0.02 µM (n = 5), with a
steep Ca2+ dependence (Hill coefficient = 4.7 ± 0.8, n = 5) (Fig. 6A).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
Single-channel conductance and calcium
sensitivity of hSK2 channels. A, calcium sensitivity of
hSK2 currents was determined from inside-out macropatches in the
presence of the indicated intracellular free Ca2+
concentrations; currents were measured at 140 mV and normalized to
that activated at saturating free Ca2+ concentrations.
Relative current amplitude is plotted as a function of the internal
free Ca2+ concentration and the data were fitted with the
Hill equation. B, single-channel activity from a
representative inside-out patch, recorded in the presence of 0.7 µM free Ca2+ at +60, 0, 50, 80, and 100
mV. C, single-channel current-voltage relation for the patch
shown in B. Data points were derived from single channel
amplitudes obtained by the fitting of a single Gaussian function to
amplitude histograms. Linear regression yielded a unitary conductance
of = 9.4 pS. With the recording solutions (see "Experimental
Procedures"), the calculated Erev = 7
mV.
|
|
Regulation of hSK2 in Jurkat T Cells--
Activation of normal
human T lymphocytes was previously shown to enhance at different
extents, expression of both Kv and KCa channel activity (20). Thus, we
checked whether hSK2 channels were modulated upon activation of Jurkat
T cells at the transcriptional, translational, and functional levels.
The hSK2 expression was compared with that of Kv1.3 channels
under the same experimental conditions. Using RT-PCR, cDNA
fragments of 797- and 445-bp lengths were specifically amplified from
hSK2 and Kv1.3 mRNAs, respectively (Fig.
7A). In some cases, a
nonspecific band of about 600 bp was also amplified using the
hSK2 primers (Fig. 7A). Following activation of
Jurkat cells for 14 h either by phytohemagglutinin A (PHA, 10 µg/ml) or by the phorbol ester TPA (0.1 µM) + ionomycin
(1 µM), there was, respectively, 46 ± 5%
(n = 3, p < 0.01) and 69 ± 4%
(n = 3, p < 0.01) down-regulation of
hSK2 mRNA as measured by quantitative RT-PCR (Fig. 7,
A and B). A corresponding 54 ± 9%
reduction in SK2 current amplitude is observed after treatment of
Jurkat cells with TPA + ionomycin for 14 h (n = 10, p < 0.01) (Fig. 8,
C and D). Treatment of TPA alone (0.1 µM) reduces to a slightly higher extent hSK2
mRNA levels when compared with treatment with ionomycin alone (1 M), with 65 ± 9 and 51 ± 4% down-regulation, respectively (Fig. 7, A and B). At the protein
level, a similar down-regulation of a specific 57-kDa hSK2
immunoreactive band is observed upon treatment of Jurkat cells with PHA
(10 µg/ml) and TPA (0.1 µM) + ionomycin (1 µM) (Fig. 8A). Paralleling the regulation at
hSK2 mRNA levels, treatment of Jurkat cells with TPA
alone produces a stronger reduction in hSK2 immunoreactive protein than
that induced by treatment with ionomycin alone (Fig. 8A). In
agreement with Northern blot analysis, no hSK2 mRNA
could be detected by RT-PCR neither in resting nor in activated
peripheral human T cells (Fig. 7C).

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 7.
Modulation of hSK2 and
Kv1.3 mRNAs following mitogenic
stimulation of Jurkat cells. A, representative
experiment illustrating quantitative RT-PCR performed to detect changes
in hSK2 and Kv1.3 mRNAs following mitogenic
stimulation (14 h) of Jurkat T cells by PHA (10 µg/ml) or by 0.1 µM TPA and 1 µM ionomycin, either alone or
in combination as indicated. Primers spanning the nucleotides
1624-2421 of hSK2 cDNA and the nucleotides 460-905 of
hKv1.3 cDNA (21), amplified respectively, a 797-bp
hSK2 and a 445-bp hKv1.3 PCR fragments. The
co-amplification of an internal control housekeeping gene, the human
S14 ribosomal protein mRNA was performed as described
(47) and amplified a 143-bp PCR fragment. Equal aliquots of each PCR
were removed and analyzed by 1.2% agarose gel electrophoresis.
B, data were quantified by scanning the labeled bands and
normalized to the 143-bp S14 signal. Values are expressed as mean ± S.E. (n = 3-5, * p < 0.01).
C, no hSK2 mRNA could be detected in resting
or activated human peripheral T cells (PHA 10 µg/ml, 48 h; or
0.1 µM TPA + 1 µM ionomycin, 48 h).
|
|

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 8.
Modulation of hSK2 and Kv1.3 channel proteins
and currents following mitogenic stimulation of Jurkat cells.
A, representative Western blots illustrating the changes in
hSK2 and Kv1.3 immunoreactive proteins following mitogenic stimulation
(14 h) of Jurkat T cells by PHA (10 µg/ml) or 0.1 µM TPA and 1 µM ionomycin, either alone or
in combination as indicated. hSK2 and Kv1.3 immunoreactive proteins
were detected as 57- and 60-kDa bands, respectively, using polyclonal
anti-rSK2 and anti-hKv1.3 antibodies. C,
representative ramp currents recorded from control and activated (0.1 µM TPA + 1 µM ionomycin, 14 h) Jurkat
cells. Currents were recorded from a holding potential of 0 mV in
external high K+ solutions by a ramp of 400 ms from 160
to +40 mV. D, statistics of the experiments as in
C. SK2 currents are significantly reduced following TPA + ionomycin treatment (n = 13, * p < 0.01).
|
|
In contrast to hSK2, Kv1.3 mRNA and
immunoreactive protein are not down-regulated by PHA treatment (10 µg, 14 h) of Jurkat cells (Fig. 7, A and
B, and Fig. 8A). PHA does not affect as well the
Jurkat Kv currents (not shown). However, treatments with TPA and
ionomycin either separately or in combination produce like for
hSK2, a down-regulation of about 50% of Kv1.3 channels at the mRNA, protein, and functional levels (Fig. 7, A and
B, and Fig. 8, A and C).
The kinase p56lck is the main non-receptor tyrosine kinase of
the Src-like family expressed in Jurkat T cells and it was shown that
the p56lck-mediated phosphorylation of the Kv1.3 K+
channel
subunit is correlated with an inhibition of Kv currents upon Fas stimulation (45). We examined the transcriptional and functional expression of hSK2 channels in normal and
p56lck-deficient Jurkat cells (LCK
cells) and
found no significant difference in the levels of hSK2 steady-state mRNAs as measured by quantitative RT-PCR (Fig.
9, C and D). The
amplitude of the apamin-sensitive SK current was very similar in
LCK
cells and in normal Jurkat cells (Fig. 9,
A and B). Interestingly, restoration and
overexpression of p56lck tyrosine kinase (LCK+
cells) into p56lck-deficient Jurkat cells produced more than
3.5-fold increase in apamin-sensitive SK currents as compared with
normal Jurkat or to LCK
cells (Fig. 9, A and
B). The increase in SK current observed in LCK+
cells was specific, as the Kv current amplitude remained the same in
normal Jurkat, in LCK
and LCK+ cells (Fig.
9E). The marked up-regulation of SK current in
LCK+ cells was accompanied by a significant increase
(70 ± 10%, n = 3, p < 0.01) in
hSK2 mRNA levels as revealed by RT-PCR (Fig. 9,
C and D).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 9.
SK2 and Kv1.3 currents in Jurkat,
LCK and LCK+ cells.
A, representative ramp currents recorded in normal (Jurkat),
p56lck-deficient (LCK ) and overexpressed
p56lck Jurkat cells (LCK+). Currents were recorded
from a holding potential of 0 mV in external high K+
solutions by a ramp of 400 ms from 160 to +40 mV. B,
statistics of the experiments as in A. SK2 current amplitude
as determined at 160 mV was significantly increased in
LCK+ cells as compared with Jurkat cells (n = 21, * p < 0.001). C, representative
experiment illustrating quantitative RT-PCR performed as in Fig.
7A, to detect differences in hSK2 mRNAs in
Jurkat, LCK , and LCK+ cells. D,
data were quantified by scanning the labeled bands and normalized to
the 143-bp S14 signal. Values are expressed as mean ± S.E. Higher
levels of hSK2 mRNAs are seen in LCK+ cells
as compared with LCK and Jurkat cells (n = 3, * p < 0.01). E, current-voltage
relations of Kv1.3 recorded in physiological solutions in Jurkat
(open squares, n = 9), LCK
(open triangles, n = 9), and
LCK+ (solid triangles, n = 10)
cells.
|
|
 |
DISCUSSION |
In this work, we have identified the apamin-sensitive KCa channel
of human leukemic Jurkat T cells as hSK2, the human isoform of the previously cloned rat SK2 (30). The hSK2
gene is encoded by 8 exons and could be assigned to chromosome 5 (q21.2-q22.1). In transfected CHO cells, hSK2 produces a
time- and voltage-independent Ca2+-activated K+
current with a unitary conductance of 9.5 pS and a
K50 for calcium of 0.7 µM. Like in
Jurkat T cells, recombinant hSK2 current is inhibited by apamin,
scyllatoxin, and dTC. In contrast to IKCa channels which are
transcriptionally induced upon activation of normal human T cells, our
results indicate that in Jurkat T cells, SK2 channels are
constitutively expressed and are down-regulated following mitogenic
stimulation. In Jurkat cells overexpressing the Src family tyrosine
kinase p56lck (LCK+), the SK2 channel activity
increases by more than 3-fold.
Human peripheral T lymphocytes express two types of K+
channels, the Kv channels activated by membrane depolarization and KCa channels which open following an increase in intracellular free Ca2+ (20). Kv1.3 channels were found to underlie
lymphocytic Kv currents while more recently, hSK4 channels (also called
hIK1, hIKCa1, or hKCa4) were shown to account for the CTX-sensitive T
cell KCa currents, also called IK or intermediate conductance (25-27,
33). Similarly, the human leukemic Jurkat T cells express two different
types of K+ channels, the Kv and KCa channels. However,
contrary to normal T cells, the Jurkat KCa channel exhibits a smaller
unitary conductance and a different pharmacology (16, 17).
While the Kv1.3 gene was shown to encode the Jurkat Kv
channels (21), the Jurkat KCa current has been identified recently as
SK2, based on the PCR amplification of a partial Jurkat
SK2 cDNA fragment (29). Here, we cloned from Jurkat T
cells a 2.5-kb full-length cDNA, hSK2, encoding the
human isoform of SK2 channels. Similar to native Jurkat KCa currents,
hSK2 produces in transfected CHO cells a time- and
voltage-independent K+ current which is sensitive to
apamin, scyllatoxin, and dTC and is insensitive to CTX and DTX. The
unitary channel conductance of hSK2 is 9.5 pS, a value very close to
that obtained previously for recombinant rSK2 (30). However,
it is noteworthy that the recombinant hSK2 unitary conductance is
somewhat larger than that determined by fluctuation analysis for the
native Jurkat SK channel (4-7 pS) (16). This difference may be
accounted for by the different methods of analysis used and the
experimental conditions, or by the existence of an auxilary subunit in
Jurkat cells. The Ca2+ sensitivity of hSK2 provides a
K0.5 of 0.7 µM, with a steep
Ca2+ dependence (
= 4.7), which is in line with the
values previously reported for rSK2 (30).
The protein encoded by hSK2 is highly homologous to its rat
protein counterpart rSK2 with 97% identity (30). Although
we did not experimentally examine the human chromosomal localization of
hSK2, a Blastn search at the GenBankTM via the
HTGS identified three matching human chromosome 5 contigs (AC010595,
AC021085, and AC025761), which retrieved one STS, D5S2065. This
analysis allowed us to assign the hSK2/KCNN2 gene to human
chromosome 5 (q21.2-q22.1) and to ascertain the genomic organization of
hSK2. Although SK and IK channel genes are subdivided into
different clusters on the phylogenetic tree (see Fig. 4A),
there is a remarkable similarity in intron-exon boundary location if
one compares our hSK2 data with those recently published for
IKCa1 and SKCa1-3 genes (44), suggesting a
common ancestral gene. It is also noteworthy that like the
IKCa1 mRNA, the hSK2 mRNA comprises short
5'- and 3'-untranslated regions (456 and 333 bp, respectively).
Our data indicate substantial differences between KCa channels of
normal human T lymphocytes and leukemic Jurkat T cells. 1) In terms of
their molecular entities as they are encoded by two different genes,
hSK4 (or hIK1, hIKCa1, and hKCa4)
(25-27, 33) and hSK2 (the present work), respectively. 2)
In terms of their basal expression at rest and their regulation
following mitogenic stimulation. Resting normal human T cells express
on average ~8 hIKCa channels/cell, along with ~300 Kv1.3
channels/cell, while resting Jurkat cells express on average ~400 SK
channels and 400 Kv1.3 channels (16, 20, 44). A number of studies have
shown that activation of normal human T cells potently induces KCa
channel activity which is accompanied by the transcriptional induction
of hSK4/hIKCa1 mRNAs (27, 33, 44). IKCa1
expression increases from an average of 8 to 300-800 channels per cell
following mitogenic activation of normal human T cells and mitogens
enhance IKCa1 promoter activity via AP1 and Ikaros-2 motifs
(44). Our results show that in Jurkat T cells, there is constitutive
expression of hSK2 channels as we determined at the mRNA, protein,
and functional levels. There is also constitutive expression of Kv1.3
channels. Following activation of Jurkat T cells by PHA, there is
neither up-regulation of SK currents nor transcriptional induction of hSK2 mRNA. Rather, there is a significant decrease in
hSK2 transcript and protein, paralleled by a marked
down-regulation of SK currents. In Jurkat cells, while hSK2 channels
are down-regulated by PHA, TPA, and to a lesser extent by ionomycin,
Kv1.3 channels appear to be insensitive to PHA treatment and are
reduced only by TPA and ionomycin exposures. Thus, Jurkat T cells
appear anomalous in their constitutive expression of hSK2 channels. In
normal human T cells, Kv1.3 channels appear essential for activation of
resting cells, while activated cells require IKCa channels for the
reactivation response (23, 33, 44). It is likely that the mechanisms governing the regulation of KCa channel activity following normal T
cell activation have been disrupted in Jurkat cells since they are
leukemic cells which have lost the control of proliferation. It is
possible that the marked down-regulation of hSK2 and Kv1.3 channels
produced by mitogenic stimulation of Jurkat cells serves as a negative
feedback to limit the activity of potassium channels (KCa and Kv) in
order to restrict proliferation of these leukemic cells. However,
Jurkat SK channels may also contribute to the positive feedback control
between cytosolic Ca2+ and membrane potential and both Kv
and KCa channel activities were suggested to sustain Ca2+
oscillations in Jurkat cells (16).
The marked increase in SK currents (more than 3.5-fold) following
overexpression of p56lck tyrosine kinase in LCK+
cells seems to involve a transcriptional up-regulation. In preliminary experiments, pretreatment of LCK+ cells with genistein (100 µM) did not affect the SK
current.2 However, a
modulation of hSK2 channels by phosphorylation should not be excluded.
The increase in SK currents is specific since the levels of Kv channel
activity appear to be similar in Jurkat, LCK
, and
LCK+ cells. Recent work suggests that ceramide via
p56lck kinase regulates Kv1.3 channel activity upon Fas
stimulation (45, 46). It will be important to check in future
experiments the possible direct modulation of hSK2 by
p56lck tyrosine kinase and to examine by analogy whether such
regulations occur for hSK4/hIKCa channels in normal human T lymphocytes.
 |
ACKNOWLEDGEMENTS |
We thank Prof. Arthur Weiss (University of
California at San Francisco) for providing the p56lck-deficient
and p56lck-overexpressing Jurkat cells, Dr. Amanda Patel for
the gift of pIRES-CD8, Sarah Etkin for skillful technical assistance,
and Dr. Ronen Alon for constructive discussions.
 |
FOOTNOTES |
*
This work was supported in part by grants from the Minerva
Foundation, the Israel Science Foundation, the Israel Ministry of
Health, and the Israel Cancer Research Fund (RCDA).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence reported in this paper for the human hSK2
sequence (KCNN2) has been submitted to the
GenBankTM/EBI Data Bank with accession number
AF239613.
Incumbent of the Philip Harris and Gerald Ronson Career
Development Chair. To whom correspondence should be addressed: Dept. of
Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel. Tel.: 972-89-342315; Fax: 972-89-344131; E-mail:
bernard. attali@weizmann.ac.il.
Published, JBC Papers in Press, September 15, 2000, DOI 10.1074/jbc.M001562200
2
Desai, A. Peretz, B. Attal, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
KCa, Ca2+-activated K+ channels;
SK, small
conductance Ca2+-activated K+ channels;
dTC, d-tubocurarine;
BK, large-conductance Ca2+- and
voltage-gated K+ channels;
IK, the intermediate conductance
Ca2+-activated K+ channels;
Kv, voltage-gated
K+ channels;
CTX, charybdotoxin;
LCK
, p56lck-deficient Jurkat cells;
LCK+, p56lck-overexpressing Jurkat cells;
DTX,
-dendrotoxin;
ORF, open reading frame;
PHA, phytohemagglutinin A;
[Ca2+]i, intracellular [Ca2+];
PCR, polymerase chain reaction;
kb, kilobase(s);
CHO, Chinese hamster ovary;
bp, base pair(s);
UTR, untranslated region;
RT-PCR, reverse
transcriptase-polymerase;
EST, expressed sequence tag;
PHA, phytohemagglutinin A;
TPA, 12-O-tetradecanoylphorbol-13-acetate;
HTGS, high-throughput
genome sequence.
 |
REFERENCES |
| 1.
|
Blatz, A.,
and Magleby, K.
(1987)
Trends Neurosci.
10,
463-467
|
| 2.
|
Sah, P.
(1996)
Trends Neurosci.
19,
150-154
|
| 3.
|
Vergara, C.,
Latorre, R.,
Marrion, N.,
and Adelman, J. P.
(1998)
Curr. Opin. Neurobiol.
8,
321-329
|
| 4.
|
Romey, G.,
Hugues, M.,
Schmid-Antomarchi, H.,
and Lazdunski, M.
(1984)
J. Physiol.
79,
259-264
|
| 5.
|
Moczydlowski, E.,
Lucchesi, K.,
and Ravindran, A.
(1988)
J. Membr. Biol
105,
95-111
|
| 6.
|
Castle, N.,
Haylett, D. G.,
and Jenkinson, D. H.
(1989)
Trends Neurosci.
12,
59-65
|
| 7.
|
Strong, P. N.
(1990)
Pharmacol. Ther.
46,
137-162
|
| 8.
|
Hugues, M.,
Duval, D.,
Kitabgi, P.,
Lazdunski, M.,
and Vincent, J.-P.
(1982)
J. Biol. Chem.
257,
2762-2769
|
| 9.
|
Hugues, M.
(1982)
Biochem. Cell Biol. Commun.
107,
1577-1582
|
| 10.
|
Hugues, M.,
Duval, D.,
Schmid, H.,
Kitabgi, P.,
Lazdunski, M.,
and Vincent, J. P.
(1982)
Life Sci.
31,
437-443
|
| 11.
|
Hugues, M.,
Schmid, H.,
Romey, G.,
Duval, D.,
Frelin, C.,
and Lazdunski, M.
(1982)
EMBO J.
1,
1039-1042
|
| 12.
|
Hugues, M.,
Romey, G.,
Duval, D.,
Vincent, J. P.,
and Lazdunski, M.
(1982)
Proc. Natl. Acad. Sci. U. S. A.
79,
1308-1312
|
| 13.
|
Lazdunski, M.,
Fosset, M.,
Hughes, M.,
Mourre, C.,
Romey, G.,
and Schmid-Antomarchi, H.
(1985)
Biochem. Soc. Symp.
50,
31-42
|
| 14.
|
Mourre, C.,
Hugues, M.,
and Lazdunski, M.
(1986)
Brain Res.
382,
239-249
|
| 15.
|
Schmid-Antonmarchi, H.,
Hugues, M.,
and Lazdunski, M.
(1986)
J. Biol. Chem.
261,
8633-8637
|
| 16.
|
Grissmer, S.,
Lewis, R. S.,
and Cahalan, M. D.
(1992)
J. Gen. Physiol.
99,
63-84
|
| 17.
|
Hanselmann, C.,
and Grissmer, S.
(1996)
J. Physiol.
496,
627-637
|
| 18.
|
Wadsworth, J. D.,
Torelli, S.,
Doorty, K. B.,
and Strong, P. N.
(1997)
Arch. Biochem. Biophys.
346,
151-160
|
| 19.
|
Pribmow, D.,
Johnson-Pais, T.,
Bond, C. T.,
Keen, J.,
Johnson, R. A.,
Janowsky, A.,
Silvia, C.,
Thayer, M.,
Maylie, J.,
and Adelman, J. P.
(1999)
Muscle & Nerve
22,
742-750
|
| 20.
|
Lewis, R. S.,
and Cahalan, M. D.
(1995)
Annu. Rev. Immunol
13,
623-653
|
| 21.
|
Attali, B.,
Romey, G.,
Honore, E.,
Schmid-Alliana, A.,
Mattei, M. G.,
Lesage, F.,
Ricard, P.,
Barhanin, J.,
and Lazdunski, M.
(1992)
J. Biol. Chem.
267,
8650-8657
|
| 22.
|
Cai, Y. C.,
Osborne, P. B.,
North, R. A.,
Dooley, D. C.,
and Douglass, J.
(1992)
DNA Cell Biol.
11,
163-172
|
| 23.
|
Grissmer, S.,
Nguyen, A. N.,
and Cahalan, M. D.
(1993)
J. Gen. Physiol.
102,
601-630
|
| 24.
|
Verheugen, J. A. H.,
Vijverberg, H. P. M.,
Oortgiesen, M.,
and Cahalan, M. D.
(1995)
J. Gen. Physiol.
105,
765-794
|
| 25.
|
Joiner, W. J.,
Wang, L. Y.,
Tang, M. D.,
and Kaczmarek, L. K.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11013-11018
|
| 26.
|
Ishii, T. M.,
Silvia, C.,
Hirschberg, B.,
Bond, C. T.,
Adelman, J. P.,
and Maylie, J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11651-11656
|
| 27.
|
Logsdon, N. J.,
Kang, J.,
Togo, J. A.,
Christian, E. P.,
and Aiyar, R. J.
(1997)
J. Biol. Chem.
272,
32723-32726
|
| 28.
|
Jensen, B. S.,
Strobaek, D.,
Christophersen, P.,
Jorgensen, T. D.,
Hansen, C.,
Silahtaroglu, A.,
Olesen, S. P.,
and Ahring, P. K.
(1998)
Am. J. Physiol.
275,
C848-C856
|
| 29.
|
Jager, H.,
Adelman, J. P.,
and Grissmer, S.
(2000)
FEBS Lett.
469,
196-202
|
| 30.
|
Kohler, M.,
Hirschberg, B.,
Bond, C. T.,
Kinzie, J. M.,
Marrion, N. V.,
Maylie, J.,
and Adelman, J. P.
(1996)
Science
273,
1709-1714
|
| 31.
|
Xia, X. M.,
Fakler, B.,
Rivard, A.,
Wayman, G.,
Johnson-Pais, T.,
Keen, J. E.,
Ishii, T.,
Hirschberg, B.,
Bond, C. T.,
Lutsenko, S.,
Maylie, J.,
and Adelman, J. P.
(1998)
Nature
395,
503-507
|
| 32.
|
Keen, J. E.,
Khawaled, R.,
Farrens, D. L.,
Neelands, T.,
Rivard, A.,
Bond, C.,
Janowsky, A.,
Fakler, B.,
Adelman, J. P.,
and Maylie, J.
(1999)
J. Neurosci.
19,
8830-8838
|
| 33.
|
Khanna, R.,
Chang, M. C.,
Joiner, W. J.,
Kaczmarek, L. K.,
and Schlichter, L. C.
(1999)
J. Biol. Chem.
274,
14838-14849
|
| 34.
|
Fanger, C. M.,
Ghanshani, S.,
Logsdon, N. J.,
Rauer, H.,
Kalman, K.,
Zhou, J.,
Beckingham, K.,
Chandy, K. G.,
Cahalan, M. D.,
and Aiyar, J.
(1999)
J. Biol. Chem.
274,
5746-5754
|
| 35.
|
Ishii, T. M.,
Maylie, J.,
and Adelman, J. P.
(1997)
J. Biol. Chem.
272,
23195-23200
|
| 36.
|
Shah, M.,
and Haylett, D. G.
(2000)
Br. J. Pharmacol.
129,
627-630
|
| 37.
|
Strobaek, D.,
Jorgensen, T. D.,
Christophersen, P.,
Ahring, P. K.,
and Olesen, S. P.
(2000)
Br. J. Pharmacol.
129,
991-999
|
| 38.
|
Hamill, O. P.,
Marty, A.,
Neher, E.,
Sakmann, B.,
and Sigworth, F. J.
(1981)
Pflugers Arch.
391,
85-100
|
| 39.
|
Sobko, A.,
Peretz, A.,
and Attali, B.
(1998)
EMBO J.
17,
4723-4734
|
| 40.
|
Jurman, M. E.,
Boland, L. M.,
Liu, Y.,
and Yellen, G.
(1994)
BioTechniques
17,
876-881
|
| 41.
|
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem
162,
156-159
|
| 42.
|
Frohman, M. A.
(1995)
in
PCR Primer, A Laboratory Manual
(Dieffenbach, C. W.
, and Dreksler, G. S., eds)
, pp. 381-409, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
|
| 43.
|
Kozak, M.
(1987)
Nucleic Acids Res.
15,
8125-8148
|
| 44.
|
Ghanshani, S.,
Wulff, H.,
Miller, M. J.,
Rohm, H.,
Neben, A.,
Gutman, G. A.,
Cahalan, M. D.,
and Chandy, K. G.
(2000)
J. Biol. Chem.
275,
37137-37149
|
| 45.
|
Szabo, I.,
Gulbins, E.,
Apfel, H.,
Zhang, X.,
Barth, P.,
Busch, A. E.,
Schlottman, K.,
Pongs, O.,
and Lang, F.
(1996)
J. Biol. Chem.
271,
20465-20469
|
| 46.
|
Gulbins, E.,
Szabo, I.,
Baltzer, K.,
and Lang, F.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
7661-7666
|
| 47.
|
Shirihai, O.,
Merchav, S.,
Attali, B.,
and Dagan, D.
(1996)
Pflugers Arch.
431,
632-638
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Takezawa, H. Cheng, A. Beck, J. Ishikawa, P. Launay, H. Kubota, J.-P. Kinet, A. Fleig, T. Yamada, and R. Penner
A Pyrazole Derivative Potently Inhibits Lymphocyte Ca2+ Influx and Cytokine Production by Facilitating Transient Receptor Potential Melastatin 4 Channel Activity
Mol. Pharmacol.,
April 1, 2006;
69(4):
1413 - 1420.
[Abstract]
[Full Text]
[PDF]
|
 |
|